behalf
studi
team
summari
backgroundinfluenza
caus
signific
morbid
mortal
despit
current
avail
treatment
anecdot
report
suggest
plasma
high
antibodi
titer
toward
influenza
may
benefit
treatment
sever
influenza
methodsw
conduct
random
openlabel
multicent
phase
trial
academ
medic
center
unit
state
assess
safeti
efficaci
antiinfluenza
plasma
hemagglutin
inhibit
hai
antibodi
titer
infect
strain
hospit
children
adult
includ
pregnant
women
sever
influenza
b
defin
hypoxia
tachypnea
randomli
assign
receiv
either
unit
pediatr
equival
antiinfluenza
plasma
plu
standard
care
ps
versu
standard
care
alon
follow
day
primari
endpoint
time
normal
patient
respiratori
statu
respiratori
rate
adult
age
defin
threshold
children
room
air
satur
oxygen
clinicaltrialsgov
identifi
findingsbetween
januari
march
particip
screen
random
particip
confirm
influenza
ps
particip
normal
respiratori
statu
day
compar
particip
estim
hazard
ratio
compar
ps
ci
six
particip
die
ps
arm
respect
ps
particip
nonsignific
reduct
day
hospit
median
vs
day
day
mechan
ventil
median
vs
day
significantli
improv
clinic
statu
day
fewer
ps
particip
experienc
sae
compar
recipi
vs
p
frequent
acut
respiratori
distress
syndrom
vs
stroke
vs
interpretationresult
phase
ii
random
trial
immun
plasma
treatment
sever
influenza
provid
support
possibl
benefit
immunotherapi
across
primari
secondari
endpoint
phase
iii
random
trial
underway
evalu
intervent
beigel
et
al
pandem
influenza
remain
global
health
threat
set
outbreak
need
new
countermeasur
rapidli
implement
plasma
therapi
use
experiment
last
year
treat
sever
infecti
diseas
begin
diphtheria
spanish
flu
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
recent
ebola
epidem
west
africa
metaanalysi
nonrandom
studi
use
convalesc
blood
product
influenza
pandem
calcul
casefat
rate
among
treat
particip
compar
among
control
cohort
studi
particip
sever
influenza
demonstr
lower
mortal
treatment
group
receiv
convalesc
plasma
vs
control
group
vs
p
although
mortal
control
group
higher
expect
compar
sever
ill
despit
encourag
data
random
control
trial
rct
immun
plasma
sever
influenza
ever
conduct
effort
rigor
evalu
role
immun
plasma
treatment
sever
influenza
conduct
rct
nonpandem
set
particip
respiratori
compromis
due
influenza
random
openlabel
multicent
phase
trial
conduct
academ
medic
center
unit
state
studi
particip
provid
written
inform
consent
studi
protocol
approv
institut
review
board
studi
site
hospit
particip
influenza
b
viru
infect
diagnos
local
rapid
antigen
polymeras
chain
reaction
pcr
either
hypoxia
room
air
satur
oxygen
tachypnea
respiratori
rate
greater
adult
age
defin
threshold
children
elig
enrol
studi
initi
restrict
onset
ill
within
day
subsequ
revis
allow
particip
enrol
regardless
onset
time
activ
viral
replic
evidenc
posit
diagnost
test
studi
initi
enrol
particip
influenza
amend
also
includ
influenza
b
particip
exclud
abo
compat
plasma
avail
particip
receiv
investig
antivir
prior
week
histori
allerg
reaction
blood
product
medic
condit
could
toler
ml
volum
clinic
suspicion
etiolog
acut
ill
primarili
due
condit
activ
influenza
viru
replic
eg
primarili
bacteri
superinfect
per
protocol
nonpregn
adult
enrol
first
year
subsequ
data
safeti
monitor
board
dsmb
review
interim
data
children
pregnant
women
also
made
elig
enrol
particip
random
onlin
random
system
ratio
receiv
either
unit
abomatch
plasma
volum
rang
mlunit
mlkg
pediatr
equival
studi
day
addit
standard
care
versu
standard
care
alon
standard
care
could
vari
depend
upon
clinic
need
patient
particip
requir
receiv
neuraminidas
inhibitor
part
treatment
comput
gener
central
random
scheme
use
stratif
age
group
pregnanc
statu
year
year
year
year
year
pregnant
year
pregnant
pregnant
random
stratifi
site
measur
diseas
sever
studi
blind
studi
use
unit
human
plasma
met
requir
fda
licens
fresh
frozen
plasma
ffp
prescreen
hemagglutin
inhibit
hai
titer
central
laboratori
unit
requir
hai
titer
least
though
unit
use
particip
influenza
geometr
mean
hai
titer
respect
rang
influenza
b
geometr
mean
hai
titer
begin
studi
plasma
collect
donor
direct
program
screen
particip
high
titer
hai
serial
collect
plasma
individu
cours
studi
plasma
collect
chang
screen
unit
plasma
blood
establish
identifi
unit
high
hai
titer
influenza
influenza
b
allow
larger
volum
plasma
collect
support
treatment
studi
studi
plasma
administ
soon
possibl
later
hour
random
rate
infus
dictat
institut
practic
two
infus
separ
least
hour
order
assess
immedi
ae
first
unit
interv
unit
could
extend
clinic
indic
particip
assess
studi
day
predos
studi
day
nasal
oropharyng
swab
influenza
pcr
collect
day
endotrach
aspir
obtain
possibl
overal
object
studi
evalu
safeti
efficaci
treatment
antiinfluenza
immun
plasma
addit
standard
care
subject
influenza
primari
efficaci
endpoint
chosen
normal
tachypnea
hypoxia
defin
normal
respiratori
rate
adult
age
defin
threshold
children
room
air
satur
oxygen
secondari
endpoint
includ
incid
durat
clinic
symptom
incid
durat
fever
time
resolut
symptom
fever
inhospit
mortal
durat
hospit
number
admiss
durat
admiss
intens
care
unit
incid
durat
supplement
oxygen
incid
ard
incid
durat
requir
mechan
ventil
disposit
home
health
care
home
health
care
transfer
longterm
care
facil
hospit
ongo
day
discharg
hospic
care
deceas
follow
last
hospit
discharg
secondari
analysi
includ
subgroup
prespecifi
formal
statist
analysi
plan
except
ordin
scale
clinic
statu
day
develop
separ
antiinfluenza
ivig
studi
clinicaltrialsgov
identifi
use
posthoc
studi
limit
data
avail
base
sampl
size
calcul
studi
howev
sampl
size
calcul
suffici
detect
decreas
median
time
normal
respiratori
statu
day
power
twosid
signific
level
efficaci
result
present
primari
efficaci
popul
pep
unless
otherwis
note
pep
includ
random
particip
influenza
infect
confirm
pcr
day
central
laboratori
analysi
per
intentiontotreat
itt
logrank
test
cox
proport
hazard
model
use
compar
primari
endpoint
treatment
use
itt
approach
primari
endpoint
particip
die
without
prior
normal
censor
day
particip
evalu
schedul
visit
either
due
prior
loss
followup
incomplet
miss
evalu
consid
normal
respiratori
statu
visit
advers
event
data
code
use
meddra
present
treatment
receiv
employe
sponsor
studi
involv
studi
design
analysi
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
januari
april
total
particip
screen
studi
figur
fifteen
particip
exclud
posit
test
influenza
site
blood
type
abo
match
plasma
avail
judg
unabl
toler
volum
exclud
reason
twenti
particip
site
enrol
least
one
particip
trial
studi
stop
end
influenza
season
within
particip
enrol
goal
ninetyeight
particip
random
eleven
particip
exclud
primari
efficaci
popul
pep
initi
sampl
pcr
neg
central
laboratori
test
median
age
random
particip
year
rang
year
eleven
children
two
pregnant
women
enrol
tabl
major
particip
underli
medic
condit
hypertens
chronic
pulmonari
diseas
common
medic
condit
present
particip
present
tabl
particip
median
day
influenza
ill
prior
enrol
receiv
antivir
prior
random
median
day
antivir
prior
enrol
particip
receiv
antibiot
protocol
dictat
antibiot
would
use
particip
receiv
naproxen
particip
receiv
azithromycin
baselin
particip
requir
oxygen
icu
mechan
ventil
adult
median
apach
ii
score
reflect
anticip
mortal
wherea
children
median
prism
iii
score
reflect
anticip
mortal
particip
random
receiv
standard
care
slightli
sever
ill
baselin
compar
random
plasma
oxygen
requir
particip
vs
mechan
ventil
particip
vs
thirti
five
particip
multilobar
infiltr
chest
xray
similar
arm
pleural
effus
common
standard
care
arm
vs
protocol
mandat
evalu
pleural
effus
though
empyema
report
loss
follow
complet
studi
day
higher
particip
receiv
standard
care
vs
though
follow
primari
endpoint
day
reach
endpoint
death
similar
vs
fortyf
particip
random
plasma
receiv
full
plan
treatment
four
particip
random
receiv
plasma
actual
receiv
plasma
see
figur
reason
one
pediatr
particip
random
standard
care
inadvert
administ
plasma
particip
receiv
plasma
first
unit
plasma
administ
median
hour
iqr
follow
random
median
hour
unit
iqr
particip
receiv
antivir
oseltamivir
monotherapi
twentyeight
particip
random
receiv
plasma
document
resolut
tachypnea
hypoxia
day
compar
control
particip
p
figur
hazard
ratio
plasma
standard
care
vs
standard
care
alon
ci
kaplanmei
analysi
caveat
studi
evalu
tachypnea
hypoxia
day
estim
median
time
resolut
tachypnea
hypoxia
day
lower
quartil
day
among
particip
random
receiv
plasma
versu
day
lower
quartil
day
among
particip
random
control
arm
due
higher
expect
loss
followup
sensit
analysi
perform
followup
censor
last
avail
assess
suffici
respiratori
statu
data
p
six
particip
random
receiv
plasma
resolv
tachypnea
hypoxia
present
screen
time
baselin
prior
receiv
plasma
compar
one
among
particip
receiv
standard
care
particip
exclud
particip
pep
random
receiv
plasma
resolut
tachypnea
hypoxia
day
compar
control
p
benefit
primarili
seen
particip
enrol
within
day
symptom
treatment
subgroup
interact
pvalu
figur
particip
random
standard
care
slightli
sever
diseas
baselin
order
evalu
influenc
baselin
differ
analysi
perform
stratifi
use
oxygen
mechan
ventil
icu
requir
presenc
ard
demonstr
similar
result
primari
analysi
stratifi
logrank
particip
random
plasma
arm
better
disposit
hospit
discharg
tabl
similar
find
note
posthoc
analysi
use
scale
clinic
statu
day
death
icu
hospit
oxygen
hospit
oxygen
hospit
return
normal
activ
hospit
return
normal
activ
better
outcom
among
particip
random
receiv
plasma
pep
across
multipl
prespecifi
measur
efficaci
also
observ
though
achiev
statist
signific
tabl
particip
random
receiv
plasma
fewer
day
hospit
random
median
vs
p
fewer
particip
hospit
readmiss
vs
fewer
particip
icu
admiss
vs
p
fewer
day
mechan
ventil
median
vs
contrast
day
oxygen
random
differ
median
vs
day
icu
random
median
vs
p
case
primari
endpoint
benefit
appear
greatest
particip
symptom
prior
random
figur
proport
hazard
model
p
without
ard
baselin
particip
random
receiv
plasma
develop
ard
wherea
receiv
standard
care
standard
care
particip
without
ard
baselin
differ
treatment
found
time
resolut
typic
influenza
symptom
p
resolut
fever
supplement
figur
six
particip
die
random
receiv
plasma
compar
among
particip
random
receiv
standard
care
random
popul
itt
analysi
p
hazard
ratio
ci
one
particip
die
receiv
plasma
die
day
plasma
infus
due
septic
shock
death
judg
relat
studi
intervent
analysi
treatment
receiv
vs
p
restrict
pep
vs
p
gave
similar
result
particip
random
receiv
plasma
log
copiesml
lower
nasal
oral
influenza
viral
load
detect
quantit
pcr
baselin
nasal
median
vs
log
copiesml
oral
vs
log
copiesml
although
viral
load
particip
endotrach
aspir
vs
log
copiesml
similar
tabl
appreci
differ
time
viru
becom
undetect
nasal
p
oral
figur
hai
titer
achiev
infus
plasma
determin
separ
particip
preexist
immun
immun
respons
strain
circul
throughout
studi
geometr
mean
hai
titer
studi
particip
baselin
ci
thirti
percent
studi
popul
seriou
advers
event
sae
fewer
plasma
recipi
control
sae
vs
p
common
sae
acut
respiratori
distress
syndrom
stroke
occur
particip
plasma
recipi
control
tabl
categori
sae
appear
frequent
among
plasma
recipi
common
advers
event
occur
first
day
hyperglycemia
increas
aspart
aminotransferas
diarrhea
anemia
fever
tabl
use
immun
plasma
recommend
primari
therapi
sever
respiratori
infecti
diseas
includ
influenza
sar
mer
howev
data
support
recommend
weak
limit
case
report
case
seri
one
case
control
studi
addit
random
control
trial
hyperimmun
antiinfluenza
immunoglobulin
show
benefit
mortal
icu
stay
hospit
stay
posthoc
analysi
particip
treat
within
day
symptom
onset
report
demonstr
reduc
mortal
vs
p
though
convers
treat
day
increas
mortal
vs
statist
analysi
report
knowledg
first
random
control
trial
demonstr
potenti
efficaci
use
immun
plasma
treatment
respiratori
viru
diseas
although
studi
abl
conclus
demonstr
efficaci
base
upon
primari
endpoint
resolut
tachypneahypoxia
fact
patient
treatment
arm
resolut
tachypneahypoxia
coupl
signific
improv
seen
clinic
statu
day
decreas
mortal
vs
multipl
secondari
endpoint
suggest
benefit
treatment
immun
plasma
furthermor
appear
maximum
benefit
accru
use
plasma
day
symptom
onset
though
definit
conclus
requir
studi
see
figur
base
data
larger
random
doubl
blind
placebo
control
trial
current
underway
clinicaltrialsgov
identifi
intervent
appear
safe
fewer
particip
random
receiv
plasma
sae
compar
particip
random
standard
care
vs
sae
appear
larg
relat
underli
influenza
complic
comorbid
condit
due
intervent
though
assess
safeti
difficult
serious
ill
popul
given
high
number
sae
ae
particip
receiv
standard
care
abil
discern
subtl
safeti
signal
associ
intervent
ill
popul
challeng
given
morbid
influenza
children
pregnant
women
import
incorpor
popul
studi
although
enrol
suffici
number
children
pregnant
women
make
discret
statement
efficaci
subpopul
shown
feasibl
would
argu
necessari
incorpor
popul
trial
novel
influenza
therapeut
sever
diseas
lack
measur
antivir
effect
difficult
interpret
need
virolog
efficaci
endpoint
influenza
therapeut
well
argu
date
even
oseltamivir
shown
conclus
efficaci
term
decreas
viral
shed
prior
studi
antiinfluenza
convalesc
plasma
report
differ
rate
decreas
viral
shed
though
cohort
design
high
mortal
control
arm
make
direct
comparison
studi
difficult
prior
studi
hyperimmun
antiinfluenza
immunoglobulin
show
virolog
benefit
day
though
previous
note
show
clinic
benefit
primari
analysi
popul
current
fda
consid
virolog
endpoint
alon
suffici
primari
endpoint
given
lack
predict
relationship
reduct
viral
titer
clinic
benefit
well
substanti
variabl
method
quantifi
viral
shed
use
hai
titer
measur
immun
prevent
influenza
well
establish
therefor
increas
hai
titer
plasma
might
anticip
decreas
viral
shed
addit
sever
hundr
unit
plasma
screen
week
support
studi
assay
need
scalabl
high
throughput
reason
unit
studi
screen
hai
howev
prior
cohort
studi
antiinfluenza
convalesc
plasma
screen
unit
neutral
antibodi
titer
nat
nat
hai
gener
relat
suffici
data
know
appropri
method
screen
plasma
unit
addit
possibl
system
administ
antibodi
suffici
permeat
mucos
surfac
order
affect
viral
replic
demonstr
differ
geometr
mean
titer
plasma
treatment
arm
compar
nontreat
particip
first
day
plasma
administr
analysi
pharmacokineticpharmacodynam
pkpd
relationship
intervent
howev
present
sever
challeng
administ
plasma
discern
intrins
immun
respons
unlik
small
molecul
baselin
titer
begin
due
preexist
immun
prior
infect
vaccin
well
immun
respons
occur
ill
onset
day
titer
higher
particip
regardless
treatment
due
adapt
immun
respons
remain
elev
baselin
month
given
complex
type
analysi
pkpd
beyond
scope
paper
abl
record
effect
immun
plasma
decreas
symptom
influenza
ill
given
sever
natur
ill
studi
popul
icu
abil
ascertain
symptom
reliabl
reproduc
may
inde
question
also
differ
arm
number
day
followup
oxygen
supplement
use
despit
suggest
improv
resolut
tachypnea
hypoxia
plasma
recipi
may
conceiv
reflect
practic
intent
omiss
delay
discontinu
supplement
oxygen
despit
resolut
hypoxia
use
ordin
scale
clinic
statu
use
level
care
done
analysi
avoid
much
variat
seen
primari
endpoint
origin
develop
use
differ
influenza
therapeut
studi
origin
analysi
plan
use
scale
encourag
see
signific
differ
outcom
treatment
arm
studi
sever
limit
limit
prior
data
effect
size
could
determin
sampl
size
calcul
end
studi
underpow
unblind
design
anoth
limit
studi
potenti
placebo
eg
salin
albumin
debat
protocol
develop
although
even
elabor
blind
scheme
studi
team
unlik
effect
blind
ultim
conclud
incorpor
placebo
await
larger
definit
trial
one
unintend
consequ
decis
observ
loss
follow
appear
somewhat
higher
particip
receiv
standard
care
compar
receiv
plasma
consent
inform
specif
studi
treatment
would
provid
suspect
particip
receiv
standard
care
less
motiv
complet
studi
visit
howev
compromis
abil
ascertain
primari
endpoint
baselin
differ
oxygen
depend
rate
mechan
ventil
apach
score
suggest
standard
care
arm
may
particip
present
sever
diseas
due
associ
age
pregnanc
outcom
influenza
chosen
primari
stratif
categori
random
limit
sampl
size
concern
addit
stratif
could
led
incomplet
fill
block
overstratif
subsequ
imbal
differ
sever
ill
like
also
account
higher
viral
burden
nasal
oropharyng
swab
baselin
standard
care
arm
varieti
reason
studi
type
prove
difficult
execut
despit
engag
establish
investig
infecti
diseas
intens
care
emerg
medicin
academ
medic
center
enrol
random
particip
took
year
major
challeng
includ
low
incid
influenza
ill
year
studi
lack
experi
blood
establish
use
plasma
investig
product
particip
famili
even
treat
physician
also
express
reluct
use
human
blood
product
diseas
like
influenza
morbid
mortal
often
underappreci
addit
challeng
uniqu
investig
product
includ
move
target
antigen
drift
circul
influenza
subtyp
need
match
evolut
time
contemporan
plasma
compar
short
shelf
life
plasma
unit
necessit
frequent
replenish
expir
unit
although
result
gener
reach
formal
statist
signific
trial
multipl
endpoint
suggest
improv
outcom
among
particip
receiv
plasma
compar
standard
care
alon
given
need
better
therapi
influenza
well
need
strategi
place
rapidli
launch
effect
therapeut
countermeasur
diseas
type
critic
import
accur
determin
efficaci
immun
plasma
consider
believ
approach
studi
larger
random
trial
note
trial
present
underway
refer
web
version
pubm
central
supplementari
materi
nasal
swab
log
copiesml
median
n
tabl
seriou
advers
event
occur
one
particip
treatment
actual
receiv
advers
event
occur
day
one
particip
